

# New Nordic Healthbrands AB (publ) <br> Three month report January - March 2014 

|  | Q1 2014 | Q1 2013 | Full Year 2013 |
| :--- | ---: | ---: | ---: |
| Net sales, KSEK | 61072 | 51027 | 227983 |
| Change in local currencies, \% | 15.1 | 0.7 | 14.2 |
| Gross profit, kSEK | 39514 | 33746 | 148789 |
| Gross margin, \% | 64,7 | 66.1 | 65.3 |
| EBITDA KSEK | 3752 | 3473 | 12154 |
| EBITDA, \% | 6,1 | 6.8 | 5.3 |
| Operating profit, kSEK | 3106 | 2723 | 9161 |
| Operating margin, \% | 5.09 | 5.34 | 4.0 |
| Profit for the period, KSEK | 2060 | 1268 | 5781 |
| Resultat per aktie*, SEK | 0.33 | 0.20 | 0.93 |
| Earnings per share*, SEK | 0.61 | 0.56 | 1.96 |

*There are no dilutive effects

## Comments by CEO Karl Kristian Bergman Jensen

We had a flying start to the year.
Revenues grew more than 15 percent in local currencies. After translation to Swedish kronor, sales amounted to a record 61.1 million SEK. The sales has grown satisfactory in all geographic areas.

EBITDA increased by 8 percent to 3.8 million SEK. Earnings per share increased 9 percent from 0.56 SEK to 0.61 SEK. Gross margin was slightly lower than the same period previous year. This is mainly a consequence of temporary changes in sales within our assortment and we expect the gross margin to return to a higher level later this year. We increased our marketing spend in the period to increase sales and help kick-start the introduction of new products in selected markets.

Our costs are under control. Staff and administrative expenses as a percent of sales bear witness to effective administration and organization. These expenses are not expected to increase significantly during the year. Our efforts in recent years to reduce depreciation and financial costs is also bearing fruit and these are now at a comfortable level. The internationalization of New Nordic is in a good momentum. We are taking market share in food supplements market, which is expected to grow by 1.6 percent in the Nordic countries, 3.4 percent in other Europe and 8.1 percent in North America in 2014. We want to increase our international sales hand in hand with increasing our profitability and earnings per share. The efficacy of our marketing efforts and the success of our new product introductions will be crucial for our results. We have several exciting launches during the year. The entire organization is very dedicated and has great focus on making our marketing even more efficient and optimizing the coming product launches.

I am full of optimism and looking forward to an exciting and rewarding year for the New Nordic and our shareholders.

## Turnover

Sales in local currencies increased by 15.1 percent during the first quarter. Converted to SEK sales increased by 19.7 percent.

## Gross profit Result for first quarter

Gross profit for amounted to SEK 39.5 million (33.7). This corresponds to a gross margin of 64.7 percent (66.1). EBITDA amounted to SEK 3.8 million (3.5). This corresponds to an EBITDA margin of 6.1 percent (6.8). Operating income amounted to SEK 3.1 million (2.7). This corresponds to an operating margin of 5.1 percent (5.3). Profit after financial items amounted to SEK 2.7 million (1.9). Profit after tax for the three month period amounted to SEK 2.1 million (1.3).

## Comments on the first quarter

The overall sales increase was satisfactory. Sales growth per region was satisfactory for other Europe and North America. For the Nordic region however, the sales was status quo. Sales in the Nordic area is strongly influenced by specific retailers reduction in inventory despite satisfactory growth of sales out of stores to end consumers plus the fact that joint marketing retailer campaigns with certain retailers has not been as effective as last year.
The gross margin decreased to 64.7 percent (66.1), which is mainly a consequence of temporary changes in sales within the company's assortment. Personnel and other external expenses increased with 18 percent and amounted to SEK 35.8 million (30,3). The main increase was related to increase in marketing costs.
Depriciations decreased by 14 percent to SEK 0.6 ( 0.8 ) and net financial items decreased by 52 percent to SEK 0.4 million SEK (0.8).

Profit after financial items increased by 44 percent and amounted to SEK 2.7 million (1.9). Profit after tax increased by 62 percent and amounted to SEK 2.1 million (1.3).

## Financial position and cash flow

Total assets as of 31 st March, 2014 amounted to $\operatorname{SEK} 93,7$ million $(87,3)$, an increase of 7 percent compared to the same time last year. Operating activities during the quarter generated a positive cash flow of SEK 2.1 million (-1.5). Cash and cash equivalents amounted to SEK 4.9 million (3.9).
The Group's equity ratio was 16.8 percent (11.1). Equity apportioned on the outstanding 6,195,200 $(6,195,200)$ shares at 31 st March, 2014 amounted to 2.54 SEK (1.57).

## Expansion

In 2014, the company will continue a strong focus on building brand leaders in a range of condition specific market segments. Profitable condition specific brands will be launched in the markets where New Nordic operate and efforts will be made to broaden the geographical distribution through reputable national exclusive distributors who can market New Nordic's brands on their own account and risk in their country. In the US, the company will focus solely on a few brands for pharmacy distribution. Simultaneously, New Nordic will start connecting with the US health food trade and build business here. New Nordic expects to increase sales and profit in all markets in which the company operates.

## Parent company

The parent company had a turnover of SEK 25.3 million $(5,9)$ in the period.
The reason for the significant increase in sales during the period is that the parent company has taken over invoicing against its subsidiaries.

## Comment on the current quarter

Sales in the first weeks of April have started well. In the US we have received our first orders from the Meijer pharmacy group.

## Transactions with related parties

There have been no material related party transactions during the period.

## Accounting principles

This report has been prepared in accordance with the Annual Accounts Act and the Financial Accounting Standards Council's recommendations.

## Certified Advicer

New Nordic Healthbrands AB's Certified Adviser is Mangold Fondkommission AB.

## Future reports

Annual meeting 30th April 2014
Sixmonth report 2014 31th July 2014
Ninemonth report 2014 31th October 2014
Full year report 2014 6th March 2015
For further information contact: Karl Kristian Bergman Jensen, CEO, kk@newnordic.com
This report has not been audited.
Malmö April 30, 2014
New Nordic Healthbrands AB (publ)
Board of Dicrectors

New Nordic Healthbrands AB
Södra Förstadsgatan 3 • SE-211 43 Malmö • Sweden
Phone: +46 40236414 • Fax: +46 40239522

## Income Statement

| (kSEK) | Q1 2014 | Q1 2013 | Full Year 2013 |
| :---: | :---: | :---: | :---: |
| Sales | 61072 | 51027 | 227983 |
| Cost of goods sold | -21 558 | -17281 | -79 194 |
| Gross profit | 39514 | 33746 | 148789 |
| Personnel expenses | -6869 | -6 288 | -26429 |
| Other external expenses | -28893 | -23 985 | -110 206 |
| EBITDA | 3752 | 3473 | 12154 |
| Depreciations | -646 | -750 | -2993 |
| Operating profit (EBIT) | 3106 | 2723 | 9161 |
| Interest and other financial items | -403 | -840 | -1267 |
| Profit after financial items | 2703 | 1883 | 7894 |
|  |  |  |  |
| Tax | -643 | -615 | -2 113 |
| Profit for the period | 2060 | 1268 | 5781 |
|  |  |  |  |
| Average number of shares | 6195200 | 6195200 | 6195200 |
| Number of shares by the end of the period* | 6195200 | 6195200 | 6195200 |
| Earnings per share, SEK | 0.33 | 0.20 | 0.93 |
| EBITDA per share, SEK | 0.61 | 0.56 | 1.96 |

*There are no dilutive effects

## Balance Sheet

| (kSEK) | Q1 2014 | Q1 2013 | Full Year 2013 |
| :---: | :---: | :---: | :---: |
| Assets |  |  |  |
| FIXED ASSETS |  |  |  |
| Intangible fixed assets | 4725 | 7015 | 5246 |
| Tangible fixed assets | 1412 | 1526 | 1514 |
| Financial assets | 9379 | 7164 | 6732 |
| Total fixed assets | 15516 | 15705 | 13492 |
| CURRENT ASSETS |  |  |  |
| Inventories | 30438 | 29926 | 30602 |
| Current receivables | 42817 | 37799 | 40122 |
| Liquid funds | 4909 | 3872 | 6072 |
| Total current assets | 78164 | 71597 | 76796 |
| Total assets | 93680 | 87302 | 90288 |
| Equity and liabilites |  |  |  |
| EQUITY | 15713 | 9729 | 13549 |
| Deffered tax | 1361 | 3853 | 1466 |
| Long-term debt | 708 | 740 | 785 |
| Short term liabilities - interest bearing | 9317 | 9684 | 10324 |
| Short term liabilities - non interest bearing | 66581 | 63296 | 64164 |
| Current liabilities | 75898 | 72980 | 74488 |
| TOTAL LIABILITIES AND EQUITY | 93680 | 87302 | 90288 |

## Change in Equity

Q1 2014

| (kSEK) Sh | Share capital | Restricted reserves | Free equity | Total equity |
| :---: | :---: | :---: | :---: | :---: |
| Balance | 6195 | 3935 | 3419 | 13549 |
| Transfer between restricted and unrestricted reserves | - 0 | 0 | 104 | 104 |
| Profit for the period | 0 | 0 | 2060 | 2060 |
| Balance | 6195 | 3935 | 5583 | 15713 |

Q1 2013

| (kSEK) | Share capital | Restricted reserves | Free equity | Total equity |
| :--- | ---: | ---: | ---: | ---: | ---: |
| Balance | $\mathbf{6 1 9 5}$ | $\mathbf{3 1 6 5}$ | $\mathbf{- 8 8 8}$ | $\mathbf{8 4 7 2}$ |
| Transfer between restricted and unrestricted reserves | 0 | 0 | -11 | -11 |
| Profit for the period | 0 | 0 | 1268 | 1268 |
| Balance | $\mathbf{6 1 9 5}$ | $\mathbf{3 1 6 5}$ | $\mathbf{9 7 2 9}$ |  |

Full Year 2013

| (kSEK) Sh | Share capital | Restricted reserves | Free equity | Total equity |
| :---: | :---: | :---: | :---: | :---: |
| Balance | 6195 | 3165 | -888 | 8472 |
| Transfer between restricted and unrestricted reserves | - 0 | 770 | -770 | 0 |
| Exchange rate differences | 0 | 0 | -704 | -704 |
| Profit for the period | 0 | 0 | 5781 | 5781 |
| Balance | 6195 | 3935 | 3419 | 13549 |

## Cash Flow Statements

| (kSEK) | Q1 2014 | Q1 2013 | Full Year 2013 |
| :---: | :---: | :---: | :---: |
| CURRENT OPERATIONS |  |  |  |
| Profit after financial items | 3106 | 2723 | 9161 |
| Adjustments for |  |  |  |
| Depreciations | 646 | 750 | 2993 |
| Other provisions | 339 | 996 | 2032 |
|  | 4091 | 4469 | 14186 |
| Interest recieved | 51 | 46 | 330 |
| Interest expense | -427 | -886 | -1597 |
| Taxation paid | -1570 | -809 | -2 419 |
| Cash flow from current operations before changes in working capital | 2145 | 2820 | 10500 |
| Cash flow from changes in working capital |  |  |  |
| Inventories | 19 | 659 | -1351 |
| Current receivables | -992 | 1582 | -1461 |
| Current liabilities | 950 | -6572 | -7 205 |
| Cash flow from current operations | 2122 | 11919 | 483 |
| INVESTMENT ACTIVITIES |  |  |  |
| Investment in intagible fixed assets | 0 | -28 | -36 |
| Investments in tangible fixed assets | -29 | -71 | -472 |
| Long term receivables | -2761 | 208 | 543 |
| Cash flow from investment activities | -2 790 | 109 | 35 |
| FINANCING ACTIVITIES |  |  |  |
| Changes in long term debt | -535 | 49 | 406 |
| Cash flow from financing activities | -535 | 49 | 406 |
| Changes in liquid funds | 1203 | 1353 | 924 |
| Liquid funds at the beginning of the period | 6072 | 5186 | 5186 |
| Exchange rate effect | 40 | 39 | -38 |
| Liquid funds at the end of the period | 4909 | 3872 | 6072 |

Key Figures

| (kSEK) | Q1 2014 | Q1 2013 | Full Year 2013 |
| :---: | :---: | :---: | :---: |
| Sales | 61072 | 51027 | 227983 |
| Gross profit | 39514 | 33746 | 148789 |
| EBITDA | 3752 | 3473 | 12154 |
| Operating profit | 3106 | 2723 | 9161 |
| Profit after financial items | 2703 | 1883 | 7894 |
| Profit after tax | 2060 | 1268 | 5781 |
| Total assets | 93680 | 87302 | 90288 |
| Return on capital employed, \% | 12.27 | 13.73 | 38.5 |
| Return on shareholders equity, \% | 13.1 | 13.0 | 42.7 |
| Equity | 15713 | 9729 | 13549 |
| Equity ratio, \% | 16.8 | 11.1 | 15.0 |
| Dept ratio | 4.96 | 7.97 | 5.66 |
| Interest coverage ratio | 6.94 | 3.12 | 3.5 |
| Investments | 29 | 99 | 508 |
| Cash flow from current operations | 2122 | -1511 | 483 |
| Cash flow from financing activities | -535 | 49 | 406 |
| Gross margin, \% | 64,7 | 66,1 | 65,3 |
| EBITDA margin, \% | 6,1 | 6,8 | 5,3 |
| Operation margin, \% | 5,09 | 5,34 | 4,0 |
| Profit margin, \% | 4,43 | 3,69 | 3,5 |
| Number of employees, average | 37 | 37 | 37 |
| Number of employees by the end of the period | 37 | 37 | 37 |
| Sales per employee | 1651 | 1379 | 6162 |
| Gross margin per emplyee | 1068 | 912 | 4021 |
| Profit per employee | 73.1 | 50.9 | 213 |
| Average number of shares in the period | 6195200 | 6195200 | 6195200 |
| Number of shares by the end of the period* | 6195200 | 6195200 | 6195200 |
| EBITDA per share, SEK | 0.61 | 0.56 | 1.96 |
| Profit per share*, SEK | 0.33 | 0.20 | 0.93 |
| Equity per share, SEK | 2.54 | 1.57 | 2.19 |

## New Nordic geographic and product segments

Revenue by segment, SEK
Diet and prediabetes
Gastro intestinal
Anti-aging
Sleep
Beauty
Brain function

Brain function

| Q1 2014 |  |
| :---: | :---: |
| MSEK | PERCENT |
| 12 | 20 |
| 4 | 6 |
| 20 | 33 |
| 4 | 7 |
| 14 | 23 |
| 7 | 11 |

Sales divided by gergraphic, SEK

Nordic
Other Europe
North America
Other World

| Q1 2014 |  |
| :---: | :---: |
| MSEK | PERCENT |
| 27 | 44 |
| 23 | 38 |
| 9 | 15 |
| 2 | 3 |


| Q1 2013 |  | Full Year 2013 |  |
| :---: | :---: | :---: | :---: |
| MSEK | PERCENT | MSEK | PERCENT |
| 12 | 24 | 59 | 26 |
| 4 | 7 | 19 | 9 |
| 14 | 28 | 60 | 26 |
| 4 | 8 | 16 | 7 |
| 10 | 19 | 49 | 21 |
| 7 | 14 | 25 | 11 |


| Q1 2013 |  | Full Year 2013 |  |
| :---: | :---: | :---: | :---: |
| MSEK | PERCENT | MSEK | PERCENT |
| 25 | 49 | 103 | 45 |
| 17 | 33 | 70 | 31 |
| 8 | 17 | 48 | 21 |
| 1 | 1 | 7 | 3 |

## Quarterly overview

|  | 2014 | 2013 |  |  |  | 2012 |  |  |  | 2011 |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Q 1 | Q 1 | Q 2 | Q 3 | Q 4 | Q 1 | Q 2 | Q 3 | Q 4 | Q 1 | Q 2 | Q 3 | Q 4 |
| Turnover MSEK | 61.1 | 51.0 | 58.9 | 58.3 | 59.7 | 52.2 | 55.5 | 49.4 | 46.7 | 47.3 | 52.3 | 51.6 | 48.2 |
| Change from last year, \% | 19.7 | -2.2 | 6.1 | 18.0 | 27.8 | 10.2 | 6.1 | -4.3 | -3.2 | 2.7 | 4.1 | 10.6 | -7.8 |
| EBITDA, MSEK | 3.8 | 3.5 | 3.6 | 3.9 | 1.1 | 3.3 | 2.0 | 2.9 | -2.7 | 3.1 | 4.1 | 6.1 | 0.8 |
| EBITDA-margin, \% | 6.1 | 6.8 | 6.1 | 6.8 | 1.9 | 6.4 | 3.5 | 5.8 | -5.7 | 6.5 | 7.9 | 11.7 | 1.7 |
| Operating result, MSEK | 3.1 | 2.7 | 2.9 | 3.2 | 0.4 | 1.4 | 0.0 | 1.0 | -3.4 | 1.1 | 2.2 | 4.1 | -1.4 |
| Operating margin, \% | 5.1 | 5.3 | 4.9 | 5.5 | 0.6 | 2.7 | 0.1 | 1.9 | -7.4 | 2.3 | 4.2 | 7.9 | -2.8 |
| Result before tax, MSEK | 2.7 | 1.9 | 2.9 | 2.5 | 0.6 | 0.7 | -1.0 | -0.3 | -4.1 | 0.3 | 1.3 | 4.0 | -3.2 |
| Result after tax, MSEK | 2.1 | 1.3 | 2.2 | 1.1 | 1.2 | 0.5 | -0.8 | -0.8 | -3.0 | 0.2 | 1.6 | 1.1 | -2.6 |
| Cash, MSEK | 4.9 | 3.9 | 3.3 | 7.6 | 6.1 | 2.0 | 2.2 | 4.5 | 5.2 | 1.0 | 1.8 | 2.6 | 1.5 |
| Stocks, MSEK | 30.4 | 29.9 | 30.1 | 29.4 | 30.6 | 27.8 | 30.7 | 28.8 | 31.1 | 26.8 | 28.8 | 22.2 | 26.9 |
| Equity, MSEK | 15.7 | 9.7 | 11.8 | 12.7 | 13.5 | 12.2 | 11.3 | 11.4 | 8.5 | 12.9 | 14,3 | 15.2 | 11.6 |
| Result per share, SEK | 0.33 | 0.20 | 0.36 | 0.18 | 0.19 | 0.08 | -0.12 | -0.14 | -0.49 | 0.03 | 0.27 | 0.17 | -0.42 |
| Equity per share, SEK | 2.54 | 1.57 | 1.90 | 2.06 | 2.19 | 1.96 | 1.82 | 1.85 | 1.37 | 2.08 | 2.31 | 2.46 | 1.88 |
| Cash flow from current operations | 0.34 | -0.24 | -0.13 | 0.53 | -0.09 | 0.29 | 0.01 | 0.39 | -0.10 | 0.10 | 0,27 | 0,45 | -0.59 |
| Solidity, \% | 16.8 | 11.1 | 12,7 | 13,7 | 15.0 | 12.6 | 11.5 | 12.7 | 9.2 | 12.4 | 12,9 | 15 | 12.3 |

Gross profit: Net sales less cost of sold goods.
Equity: Equity as a percentage of total assets.
Leverage ratio: The ratio of total liabilities and equity.
Profit margin: Profit after financial items plus financial expenses divided by financial expenses.
Return on equity: Net income as a percentage of shareholders' equity at period end.
Capital employed: Total assets less non-interest-bearing provisions and liabilities.
Return on capital employed: Profit after financial items
plus financial expenses divided by capital employed.
Investments: Investments in tangible and intangible assets.
Gross margin: Gross profit as a percentage of net sales.
EBITDA margin: Operating income before depreciation and amortization as a percentage of net sales.
Operating margin: Operating profit after depreciation and amortization as a percentage of net sales.
Profit margin: Profit after financial items as a percentage of net sales.
Revenue per employee: Net sales divided by the average number of employees.
Gross profit per employee: Gross profit divided by the average number of employees.
Profit per employee: Profit after financial items divided by the average number of employees.
Earnings per share: Profit after tax divided by the average number of shares.
Equity per share: Shareholders' equity divided by shares outstanding at period end.

